Health Phys. 1985 Oct;49(4):559-661.
An analysis and evaluation of 241Am in the whole body of a donor to the U.S. Transuranium Registry (USTR) is presented in five parts. The USTR donor's pertinent medical history, autopsy findings and antemortem evaluations of intake and systemic burden are described in Parts I and II. The donor was a 49-yr-old male Caucasian radiochemist who died of metastic melanoma in 1979. His work with actinide elements began in 1952, and the greatest potential for intake of 241Am was when he used an unsealed 241Am source in his doctoral research (1952-54). The first indication that an intake had occurred was the detection of 241Am in a urine sample collected in 1958 as part of an internal dosimetry surveillance program. In-vivo estimates of the initial 241Am intake, based on sporadic urine samples and three sets of external photon measurements, ranged from 0.23-1.1 muCi depending on the calculational models and calibration factors used. No chelation therapy was applied. The time of intake was estimated to be approximately 25 yr before death. External photon measurements made on the donor's body and dissected bones, presented in Part III, have yielded new and more accurate calibration factors for external in-vivo measurement of the 60-keV gamma rays of 241Am and the 13.2- and 14-keV x rays of 239Pu and 238Pu. The symmetrical distribution of 241Am in the bones of the right and left sides of the body and the reliability of total skeletal 241Am estimated from external measurements of 241Am in the head were confirmed. The soft tissues and about one-half of the skeleton were weighed wet, ashed, reweighed and analyzed radiochemically for 241Am, as described in Part IV. The measured total 241Am in the body was 147.4 nCi, distributed as follows: soft tissues of left hand, 1.9%; liver, 6.3%; respiratory tract tissues, 1.5%; other organs, 0.9%; combined structural soft tissues (muscle, skin, connective tissue), 8.6%; mineralized tissues (bones, teeth), 80%. The expectations of similar 241Am concentrations in bones of grossly similar structure and also in parts of bones of similar microscopic structure were confirmed.(ABSTRACT TRUNCATED AT 400 WORDS)
本文分五个部分介绍了对一名美国超铀元素登记处(USTR)捐赠者全身钚 - 241的分析与评估。第一部分和第二部分描述了该USTR捐赠者的相关病史、尸检结果以及生前摄入和全身负荷的评估情况。该捐赠者是一名49岁的白人男性放射化学家,于1979年死于转移性黑色素瘤。他从1952年开始从事锕系元素研究,摄入钚 - 241的最大可能性发生在他博士研究期间(1952 - 1954年)使用未密封的钚 - 241源时。摄入发生的首个迹象是在1958年作为内部剂量监测计划一部分收集的尿液样本中检测到钚 - 241。根据零星的尿液样本和三组外部光子测量结果,基于不同的计算模型和校准因子,对最初钚 - 241摄入量的体内估计值在0.23 - 1.1微居里之间。未进行螯合治疗。摄入时间估计约在死亡前25年。第三部分介绍了对捐赠者身体和解剖骨骼进行的外部光子测量,得出了用于钚 - 241 60千电子伏特γ射线以及钚 - 239和钚 - 238的13.2千电子伏特和14千电子伏特X射线外部体内测量的新的、更准确的校准因子。证实了钚 - 241在身体左右两侧骨骼中的对称分布以及从头部钚 - 241外部测量估计的全身骨骼钚 - 241的可靠性。如第四部分所述,对软组织和大约一半的骨骼进行湿重称量、灰化、重新称量,并对钚 - 241进行放射化学分析。体内测量的钚 - 241总量为147.4纳居里,分布如下:左手软组织,1.9%;肝脏,6.3%;呼吸道组织,1.5%;其他器官,0.9%;联合结构软组织(肌肉、皮肤、结缔组织),8.6%;矿化组织(骨骼、牙齿),80%。证实了在结构大体相似以及微观结构部分相似的骨骼中钚 - 241浓度相似的预期。(摘要截于400字)